Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Jazz Pharmaceuticals Shares Fell Out of Bed

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ  ) dipped as much as 10% after the company reported its first-quarter results and following regulatory comments with regard to generic competition to its lead drug.

So what: For the quarter, Jazz reported an adjusted profit of $1.37 per share as product revenue nearly doubled to $194.6 million. As has been the case in the past, narcolepsy drug Xyrem led the charge with sales jumping 60% to $117.5 million. Comparatively, Wall Street had only expected EPS of $1.36 on $190.3 million in sales, yielding another earnings beat for shareholders. Looking forward, Jazz also boosted its EPS forecast to a range of $6.10-$6.30 from its previous guidance of $5.70-$5.90.

While this would normally send a company higher, comments from Jazz's regulatory filing that the Food and Drug Administration may approve a generic version of Xyrem being developed by Roxane Labs sent shareholders scurrying for the exits. With Xyrem comprising 60% of sales, that could be a big problem.

Now what: While the potential competition for Xyrem is certainly unwelcome news, an ongoing lawsuit between Jazz and Roxane appears even more likely now to involve a cash settlement for Roxane rather than Jazz allowing Roxane to bring the generic drug to market. Outside of what seem to largely overblown fears, Jazz continues to deliver incredible growth and profitability. Jazz is now valued at less than nine times the midpoint of this year's forecast with a revenue growth rate of 40% this year. If that wasn't enough, it also authorized a $200 million share repurchase program. If you are looking for significantly undervalued biopharmaceutical companies, I'd highly suggest digging deeper into Jazz Pharmaceuticals.

Craving more input? Start by adding Jazz Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biopharmaceutical companies like Jazz, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2418165, ~/Articles/ArticleHandler.aspx, 9/30/2016 1:26:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
JAZZ $123.01 Down -2.75 -2.19%
Jazz Pharmaceutica… CAPS Rating: ***